{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:27Z","timestamp":1794047487354,"version":"4.8.0"},"reference-count":36,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Carfilzomib, lenalidomide, and dexamethasone (KRd) combination therapy improves the survival of patients with relapsed and\/or refractory multiple myeloma (RRMM). Nonetheless, evidence on the use of KRd in Asian populations remains scarce. Accordingly, this study aimed to investigate this regimen\u2019s efficacy in a large group of patients. This retrospective study included patients with RRMM who were treated with KRd at 21 centers between February 2018 and October 2020. Overall, 364 patients were included (median age, 63 years). The overall response rate was 90% in response-evaluable patients, including 69% who achieved a very good partial response or deeper responses. With a median follow-up duration of 34.8 months, the median progression-free survival (PFS) was 23.4 months and overall survival (OS) was 59.5 months. Among adverse factors affecting PFS, high-risk cytogenetics, extramedullary disease, and doubling of monoclonal protein within 2-3 months prior to start of KRd treatment significantly decreased PFS and OS in multivariate analyses. Patients who underwent post-KRd stem cell transplantation (i.e., delayed transplant) showed prolonged PFS and OS. Grade 3 or higher adverse events (AE) were observed in 56% of the patients, and non-fatal or fatal AE that resulted in discontinuation of KRd were reported in 7% and 2% of patients, respectively. Cardiovascular toxicity was comparable to that reported in the ASPIRE study. In summary, KRd was effective in a large, real-world cohort of patients with RRMM with long-term follow-up. These findings may further inform treatment choices in the treatment of patients with RRMM.<\/jats:p>","DOI":"10.3324\/haematol.2024.285534","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:36:36Z","timestamp":1717688196000},"page":"3681-3692","source":"Crossref","is-referenced-by-count":2,"title":["Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study"],"prefix":"10.3324","volume":"109","author":[{"given":"Ji Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongheon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ho","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Shin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungwoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"Uhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Ryeong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"68654","doi-asserted-by":"crossref","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372(2):142-152.","DOI":"10.1056\/NEJMoa1411321"},{"key":"68655","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Madduri D, Usmani SZ. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021; 398(10297):314-324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"68656","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Oriol A, Nahi H. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375(14):1319-1331.","DOI":"10.1056\/NEJMoa1607751"},{"key":"68657","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023; 29(9):2259-2267.","DOI":"10.1038\/s41591-023-02528-9"},{"key":"68658","doi-asserted-by":"crossref","unstructured":"Lonial S, Dimopoulos M, Palumbo A. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015; 373(7):621-631.","DOI":"10.1056\/NEJMoa1505654"},{"key":"68659","doi-asserted-by":"crossref","unstructured":"Moreau P, Masszi T, Grzasko N. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 374(17):1621-1634.","DOI":"10.1056\/NEJMoa1516282"},{"key":"68660","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD Jr, Shah N. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8):705-716.","DOI":"10.1056\/NEJMoa2024850"},{"key":"68661","doi-asserted-by":"crossref","unstructured":"Costa LJ, Chhabra S, Medvedova E. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022; 40(25):2901-2912.","DOI":"10.1200\/JCO.21.01935"},{"key":"68662","doi-asserted-by":"crossref","unstructured":"Kumar SK, Jacobus SJ, Cohen AD. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020; 21(10):1317-1330.","DOI":"10.1016\/S1470-2045(20)30452-6"},{"key":"68663","doi-asserted-by":"crossref","unstructured":"Leypoldt LB, Besemer B, Asemissen AM. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia. 2022; 36(3):885-888.","DOI":"10.1038\/s41375-021-01431-x"},{"key":"68664","doi-asserted-by":"crossref","unstructured":"Roussel M, Lauwers-Cances V, Wuilleme S. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood. 2021; 138(2):113-121.","DOI":"10.1182\/blood.2021010744"},{"key":"68665","doi-asserted-by":"crossref","unstructured":"Richardson PG, San Miguel JF, Moreau P. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018; 8(11):109.","DOI":"10.1038\/s41408-018-0141-0"},{"key":"68666","doi-asserted-by":"crossref","unstructured":"Sugiura I, Suzuki K, Ri M. Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma. Int J Hematol. 2020; 111(1):57-64.","DOI":"10.1007\/s12185-019-02754-3"},{"key":"68667","doi-asserted-by":"crossref","unstructured":"Lee JH, Park Y, Kang KW. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. Ann Hematol. 2021; 100(8):2051-2059.","DOI":"10.1007\/s00277-021-04407-0"},{"key":"68668","doi-asserted-by":"crossref","unstructured":"Takezako N, Shibayama H, Handa H. Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR. Int J Hematol. 2021; 113(2):219-230.","DOI":"10.1007\/s12185-020-03013-6"},{"key":"68669","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson KC, Bergsagel PL. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117(18):4696-4700.","DOI":"10.1182\/blood-2010-10-300970"},{"key":"68670","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"68671","doi-asserted-by":"crossref","unstructured":"Lee JH, Kim SH. Treatment of relapsed and refractory multiple myeloma. Blood Res. 2020; 55(S1):S43-S53.","DOI":"10.5045\/br.2020.S008"},{"key":"68672","doi-asserted-by":"crossref","unstructured":"Antonioli E, Pilerci S, Attucci I. Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network. Front Oncol. 2023; 13:1162990.","DOI":"10.3389\/fonc.2023.1162990"},{"key":"68673","doi-asserted-by":"crossref","unstructured":"Martino EA, Conticello C, Zamagni E. Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials. Hematol Oncol. 2022; 40(5):1009-1019.","DOI":"10.1002\/hon.3035"},{"key":"68674","doi-asserted-by":"crossref","unstructured":"Leleu X, Katodritou E, Kuehr T. Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel. EJHaem. 2023; 4(1):174-183.","DOI":"10.1002\/jha2.595"},{"key":"68675","doi-asserted-by":"crossref","unstructured":"Kawaji-Kanayama Y, Kobayashi T, Muramatsu A. Prognostic impact of resistance to bortezomib and\/or lenalidomide in carfilzomib-based therapies for relapsed\/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients. Cancer Rep (Hoboken). 2022; 5(2):e1476.","DOI":"10.1002\/cnr2.1476"},{"key":"68676","doi-asserted-by":"crossref","unstructured":"Blade J, Beksac M, Caers J. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022; 12(3):45.","DOI":"10.1038\/s41408-022-00643-3"},{"key":"68677","doi-asserted-by":"crossref","unstructured":"Cohen YC, Morillo D, Gatt ME. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) [abstract]. J Clin Oncol. 2023; 41(16_suppl):8002.","DOI":"10.1200\/JCO.2023.41.16_suppl.8002"},{"key":"68678","doi-asserted-by":"crossref","unstructured":"Sonneveld P. Management of multiple myeloma in the relapsed\/ refractory patient. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):508-517.","DOI":"10.1182\/asheducation-2017.1.508"},{"key":"68679","doi-asserted-by":"crossref","unstructured":"McCarthy PL, Owzar K, Hofmeister CC. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1770-1781.","DOI":"10.1056\/NEJMoa1114083"},{"key":"68680","doi-asserted-by":"crossref","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014; 371(10):906-917.","DOI":"10.1056\/NEJMoa1402551"},{"key":"68681","doi-asserted-by":"crossref","unstructured":"Richardson PG, Jacobus SJ, Weller EA. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022; 387(2):132-147.","DOI":"10.1056\/NEJMoa2204925"},{"key":"68682","doi-asserted-by":"crossref","unstructured":"Baertsch MA, Fougereau M, Hielscher T. Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma. Cancers (Basel). 2021; 13(18):4706.","DOI":"10.3390\/cancers13184706"},{"key":"68683","doi-asserted-by":"crossref","unstructured":"Byun JM, Yoon SS, Koh Y. Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd). Ther Adv Hematol. 2020; 11:2040620720921046.","DOI":"10.1177\/2040620720921046"},{"key":"68684","doi-asserted-by":"crossref","unstructured":"Miguel JS, Weisel K, Moreau P. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14(11):1055-1066.","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"68685","doi-asserted-by":"crossref","unstructured":"Richardson PG, Oriol A, Beksac M. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(6):781-794.","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"68686","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(6):801-812.","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"68687","doi-asserted-by":"crossref","unstructured":"Richardson PG, Perrot A, Miguel JS. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 2024; 109(7):2239-2249.","DOI":"10.3324\/haematol.2023.284325"},{"key":"68688","doi-asserted-by":"crossref","unstructured":"Ball S, Behera TR, Anwer F, Chakraborty R. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol. 2020; 99(6):1265-1271.","DOI":"10.1007\/s00277-020-04062-x"},{"key":"68689","doi-asserted-by":"crossref","unstructured":"Musto P, Anderson KC, Attal M. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017; 28(2):228-245.","DOI":"10.1093\/annonc\/mdw606"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285534\/77124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285534\/77711","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11641\/77124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:37Z","timestamp":1794045997000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285534","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}